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A  variety of immunologic and immunopathologic processes are  known to 
operate during the course of a viral infection (1). Despite a vast literature on 
mechanisms ofhumoral and cellular immunity  in viral infections and considera- 
ble information on the replication of viruses in cells of  the immune system, there 
are still few experimental data on the existence or importance of immediate 
hypersensitivity (allergic) reactions in viral diseases. 
Clinical studies dating back almost 40 yr have suggested that upper respiratory tract 
infections  can  precipitate  or  potentiate  attacks  of bronchial  asthma  (2-17).  Several 
reports also have shown that viral infections are associated with recurrence of wheezing 
in asthmatic patients  (2, 3, 5, 7-16). Still other studies have shown that viral infections 
(e.g., influenza) can increase bronchial sensitivity to drugs such as methacholine (4, 6, 9). 
By viral  isolation and serologic techniques,  a  variety of viruses  including respiratory 
syncytial virus, parainfluenza virus, corona virus, and rhinoviruses have been identified 
in patients with asthma (3,  5, 8, 10-16). 
The release of histamine from leukocytes (basophils) of allergic individuals 
after stimulation with ragweed antigen E or anti-IgE has proved to be a reliable 
in vitro model for immediate hypersensitivity reactions (18-20). The present 
investigation using this in vitro model was initiated to study the capacity of 
several common viruses to release histamine from leukocytes. 
Materials and Methods 
Reagents.  Tris buffer was purchased from Sigma Chemical Co., St. Louis, Mo. Human serum 
albumin (HSA) 1 was obtained from Behring Diagnostics, American Hoechst Corp., Somerville, 
N.  J.  Ragweed antigen E  and human leukocyte interferon prepared  with Sendai  virus were 
obtained  from  the  Research  Reagent  Branch,  National  Institute  of Allergy  and  Infectious 
Diseases,  National Institutes of Health,  Bethesda, Md.  Human fibroblast interferon, prepared 
1  Abbreviations used in this paper: AbN/ml, antibody nitrogen/ml; Adeno-1, adenovirus type 1; 
Antigen E, ragweed antigen E; EDTA, ethylenediaminetetraacetic acid; EIDso, 50% egg infectious 
doses; FBS, fetal bovine serum; HSA, human serum albumin; HSV-1, herpes simplex virus, type 1; 
Influenza A,  influenza virus,  type A  (PR-8 strain);  MEM,  minumum essential  medium; moi, 
multiplicity of input (infection); Poly I:Poly C, poly-riboinosinic acid:poly-ribocytidilic acid; PBS, 
phosphate-buffered saline;  PFU,  plaque-forming units;  PRK,  primary rabbit kidney; Sendai, 
parainfluenza  virus,  type 1 (Sendai);  SFV-7,  simian  foamy virus,  type 7; TCIDso, 50% tissue 
culture infectious doses; VSV, vesicular stomatitis virus. 
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with poly I:poly C, was obtained from the Laboratory of Viral Diseases, NIAID. Mouse interferon 
induced by NDV in  C-243-3  mouse cells was  obtained  from Bionetics,  Kensington,  Md.  Anti- 
human  IgE  (Fc specific) was  kindly  provided by Dr.  K.  Ishizaka,  Johns  Hopkins  University, 
Baltimore, Md. 
Buffers and Media.  Both Eagle's minimum essential medium (MEM) and RPMI 1640 medium 
were supplemented with penicillin (50 U/ml), streptomycin (50/~g/ml), fungizone (0.125  ftg/ml), 
and 2% or 10% fetal bovine serum (FBS) heat inactivated at 56°C for 30 rain. Primary rabbit kidney 
(PRK) cells were maintained in MEM with 2% FBS. 
Tris A-buffered saline (Tris A, pH 7.4) contained 120 mM NaC1, 5 mM KCI, 24 mM Tris, and 
0.03% HSA. Tris A-EDTA is Tris A with 4 mM EDTA and Tris ACM is Tris A with 1 mM Ca ++ and 
0.5 mM Mg  ++. 
Virus Preparation.  Herpes simplex virus type 1 (HSV-1), adenovirus type 1 (Adeno-1), and 
simian foamy virus type 7 (SFV-7) were propagated and assayed in PRK cells. Influenza virus type 
A  (PR-8) and parainfluensa virus type 1 (Sendal) were propagated and assayed by inoculation of 
the allantoic fluid of embryonating hen's eggs. Virus pools, uninfected PRK cell controls,  and 
allantoic fluids were centrifuged at 2,000 rpm for 10 rain to remove cell debris.  The supernatant 
fluids were centrifuged at  30,000  rpm  for 2 h  and the pellets were resuspended  in Dulbecco's 
phosphate-buffered  saline  (PBS) to 1/10 the original volume.  Single virus pools containing the 
following titers were used throughout the study: HSV-1, 1.3  × 10  s plaque-forming units (PFU)/ml; 
Adeno-1,  5.6  ×  107  tissue  culture  infectious  dosesso  (TCIDso)/ml;  SFV-7,  1  x  10  e  TCID~/ml; 
Influenza A, 3  ×  109 egg infectious dosesso  (EIDso)/ml; and Sendai, 3  ×  10 ~9 EID~o/ml. 
Leukocyte Preparation.  Human peripheral blood was mixed with 2.25 ml of Dextran (Dextran 
6% wt/vol in saline, Abbott Laboratories, North Chicago, Ill.) supplemented with 0.25 ml of 15% 
glucose and 1.0 ml of 0.1 M EDTA per 10 ml of blood. The mixture was allowed to settle at room 
temperature  for  about  90  rain.  The  leukocyte-rich  plasma  was  removed  and  the  cells were 
sedimented at 1,200 rpm for 8 rain at 4°C and suspended in Tris A-EDTA. Removal of red blood 
cells was accomplished by a  30-s hypotonic shock. After sequential washes in Tris A-EDTA and 
RPMI medium, the leukocytes were resuspended in RPMI medium containing 2% FBS (21). 
Histamine Release Reaction.  Leukocyte suspensions, containing about 5 x  10  s cells in 0.5 ml, 
were incubated with either an equal volume of infectious virus or the equivalent amount of UV- 
inactivated virus or the appropriate control media. Except where stated,  a virus:cell ratio of 1:1, 
expressed as the multiplicity of infection (moi), was used. After incubation at 37°C in a  5% COs 
atmosphere for 2 h, the cells were washed, resuspended in RPMI medium, and incubated for an 
additional 22 h  at 37°C.  All experiments were performed at least twice and in each experiment 
reactions were set up in duplicate. Controls consisted of media, uninfected PRK cells, or allantoic 
fluid prepared and diluted in the same manner as the virus pools. 
At the end of the 24-h incubation period, the leukocytes were sedimented by centrifugation at 
1,100  rpm  for 8 rain  and  the supernatant  fluids were saved for histamine  assay  or interferon 
titration.  The cells were then  washed once with Tris A  and resuspended  with an appropriate 
amount of Tris ACM. Duplicate cell samples in 0.1 ml vol were incubated at 37°C with an equal 
volume of serial dilutions of ragweed antigen E or anti-human IgE. Ai~r 45 min the tubes were 
transferred to an icebath and 0.3 ml of cold Tris ACM was added.  The cells were centrifuged at 
1,700 rpm for 15 min at 4°C and the supernatant fluids were assayed for histamine. Total cellular 
histamine  content,  expressed  as  "completes," was  determined  by  lysis  of leukocytes with  3% 
perchloric acid.  The histamine released into the supernatant  fluids of the "blanks" which con- 
tained cells and Tris ACM did not exceed 10% of the total cellular histamine. 
Histamine Assay.  Histamine was assayed by an automated fluorometric technique (22,  23). 
Percent histamine release was calculated by the formula: % release =  100 (el -/~/~ -/~), where e, = 
fluorometric  readings  for  experimental  supernates,  6  =  mean  of blanks,  and  ~  =  mean  of 
completes. The data were analyzed by either the standard t test for two means, or by paired t tests 
when two histamine release curves were compared. 
Interferon Assay.  Interferon  activity  in  the  supernatant  fluids  of leukocyte  cultures  was 
assayed  by  a  modification of the microplate method developed by  Green  et al.  (24). In brief, 
monolayers  of WISH cells in  microplates  were  incubated  for 5  h  at  37°C  with  serial twofold 
dilutions of interferon samples in a 0.1-ml vol. The cells were then challenged with 30-50 PFU of 
VSV. At the end of 1 h, the virus inoculum was removed and the cells were washed and refed with 
0.1 ml of MEM supplemented with 2% FBS and 0.75% methylcellulose. After 18 h at 37°C, the cells 894  ENHANCEMENT  OF  IgE-MEDIATED  HISTAMINE  RELEASE 
TABLE  I 
Histamine Content of Supernatant Fluids in Leukocyte  Cultures  after Incubation with 
HSV-1, Influenza A, and Adeno-1 for 24 h 
Treatment of  Number of  Number of 
Virus*  virus  leukocyte  tests per- 
donors  formed 
Histamine release (%)$ 
Control  Virus 
HSV-1  None  5  7  5.2  ___  0.5  5.8  +-- 0.4§ 
HSV-1  UV  5  6  6.1  _+  0.4  6.9 -+ 0.4§ 
Influenza A  None  6  12  5.0  --+_ 0.7  5.2  _+  0.6§ 
Influenza A  UV or heat  4  7  5.5  +_  0.6  5.8  +- 0.3§ 
Adeno-1  None  2  3  5.1  ~  0.6  5.2  +_ 0.4§ 
* moi of 0.1 or 1.0. 
$ Mean +- SE. 
§ P  >  0.1  (standard t test for percent histamine release between control media and virus). 
were fixed with ethanol and stained with Giemsa's solution and viral plaques were counted. The 
interferon titer was expressed as the reciprocal of the highest dilution that reduced VSV plaque 
counts by 50%. 
Results 
Inability  of Viruses  to Release Histamine  from Leukocyte  Cultures.  The 
initial experiments were designed to see whether the incubation of viruses with 
leukocytes caused  the  release  of histamine.  Peripheral  blood  leukocytes ob- 
tained from both allergic and nonallergic  human donors were incubated with 
HSV-1, Influenza A, and Adeno-1 at an moi of 0.1 or 1.0. After 24 h of incubation 
at 37°C in a  5% CO2 atmosphere, the supernatant fluids were assayed for their 
histamine content. As seen in Table I, the amount of histamine released into the 
supernatant fluids was not altered by the addition of either infectious or inacti- 
vated viruses to the leukocyte cultures. There also was no appreciable change in 
the cellular histamine content (data not shown). 
Effect of Viruses on Histamine Release Induced by Anti-IgE 
INFECTIOUS VIRUS.  Leukocytes were  incubated  with  infectious  viruses  or 
control media for 24 h  and then challenged  with anti-IgE  for 45 min and the 
amount of histamine released into the supernatant fluids was determined. The 
results of a typical experiment with the cells from one individual are shown in 
Fig.  1. Leukocytes that had been treated with HSV-1 showed enhanced hista- 
mine release when exposed to anti-IgE  (P <  0.001). At the optimum anti-IgE 
concentration,  the  cells cultured  with  control  media released  20%  histamine 
whereas cells cultured with HSV-1 released 36% (Fig. 1 a). Similarly, leukocytes 
incubated with Influenza A and then challenged with anti-IgE showed enhanced 
histamine  release  (P  <  0.001).  At optimum  concentrations  of anti-IgE,  cells 
treated  with  control  allanteic  fluids  released  22%  histamine,  whereas  cells 
treated with Influenza A released 51% histamine  (Fig.  1 b). Incubation of cells 
with Adeno-1 also resulted in a  statistically significant increase in histamine 
release (P <  0.001), although the absolute enhancement was not as pronounced 
as with the other viruses (Fig.  lc). 
UV-INACTIVATED  VIRUS  AND  LATEX  BEADS.  Leukocytes were preincubated 
with infectious or UV-inactivated virus. After 24 h of incubation the cells were S.  IDA,  J.  J.  HOOKS,  R.  P.  SIRAGANIAN,  AND  A.  L.  NOTKINS  895 
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Fro.  1.  Enhanced histamine release from leukocytes incubated with infectious viruses. 
Leukocytes were incubated for 24 h  with HSV-1, Influenza A, or Adeno-1. The cells were 
then washed and the amount of histamine released after challenge with different concentra- 
tions of anti-IgE was determined. 
challenged with different concentrations of anti-IgE. The data in Fig. 2 show 
that leukocytes incubated with either infectious or UV-inactivated virus re- 
leased significantly more histamine than leukocytes  exposed to control media (P 
<  0.001). Paired t tests revealed no significant difference between the curves 
generated by  infectious vs.  UV-inactivated virus  (P  >  0.1). In  subsequent 
histamine release experiments, UV-inactivated viruses were used. 
To see if the increase in histamine release was due to activation of phagocyte- 
sis,  leukocytes were  incubated with  latex  beads  for  24  h.  Analysis of the 
supernatant fluids after incubation of the leukocytes with anti-IgE failed to 
reveal any enhancement of histamine release (data not shown). 
DOSE-RESPONSE STUDIES.  The relationship between the concentration of vi- 
rus (HSV-1) incubated with leukocytes and the resulting increase in histamine 896  ENHANCEMENT  OF  IgE-MEDIATED  HISTAMINE  RELEASE 
50 
40 
Iz: 
O0 
"1" 
z 
L~ 
re" 
#- 
30 
20 
10 
--  -- HSV-1 
• ---"  HSV -1  (UV) 
o---o Control  Media  (UV) 
50 
Influenza A 
=--4 Influenza A  (UV) 
_  o---oControl  Media  (UV) 
40 
20 
10 
10-3  10-2  10-1 
ANTI-IgE (p-g AbN/ml) 
Fro.  2.  Enhancement of histamine release by infectious or UV-inactivated viruses. Leu- 
kocytes were incubated for 24 h  with virus or control media. The cells were then washed, 
challenged with different concentrations of anti-IgE, and the amount of histamine released 
was determined. 
release is shown in Fig. 3. A significant enhancement of histamine release (P < 
0.001)  was  observed when  the  ratio  of virus to leukocytes  (moi)  was  0.01  or 
greater.  At  an  moi  of 0.001  there  was  no  significant  increase  in  histamine 
release (P >  0.1). 
Relationship between Histamine Release and Interferon Activity.  The  ca- 
pacity of viruses to enhance  histamine  release  after challenge  with ragweed 
antigen E or anti-IgE was tested with leukocytes from different donors. The data 
in Table II show that  HSV-1 enhanced  histamine  release in  six out of seven 
donors (P <  0.001).  Leukocytes from tim seventh donor released high amounts of 
histamine on challenge with anti-IgE and the presence of virus did not result in 
further enhancement. 
The demonstration that both infectious and UV-inactivated virus enhanced 
histamine release indicated that viral replication was not required,  and raised 
the  possibility  that  enhancement  might  be  immune  specific.  To  study  this 
possibility,  the relationship  between the level of anti-HSV neutralizing  anti- 
body and histamine  release was investigated.  Preliminary  experiments  (data 
not  shown)  revealed  that  exposure  of leukocytes from  anti-HSV-1  negative S.  IDA~  J.  J.  HOOKS~  R.  P.  SIRAGANIAN~  AND  A.  L.  NOTKINS  897 
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Fro.  3.  Relationship between virus concentration and histamine re]ease. Leukocyt~s were 
incubated with different concentrations of UV-inactivated HSV-1  and at the end of 24 h 
challenged with anti-IgE. 
TABLE  II 
Relationship between Enhanced Histamine Release and Interferon Activity in 
Supernatant Fluids from Leukocytes Incubated with HSV-1 
Treatment of Leukocytes 
Histamine release  Interferon titer 
(%)  (U/0.1 ml) 
Donors  t  values 
Concentra-  Stimulant  Control  Virus  Control  Virus 
tion* 
1  Antigen  E  5  ×  10 -3  45.9  78.8  26.49§  <10  320 
2  Antigen E  3  ×  10 -3  38.6  61.4  12.24§  <10  20 
3  Anti-IgE  1 x  10-'  14.1  51,5  9.13§  <10  320 
4  Anti-IgE  1 x  10-'  9.2  43.4  4.44§  <10  160 
5  Anti-IgE  1 x  10-'  24.0  43.6  7.75§  <10  40 
61[  Anti-IgE  3  x  10 -z  19.5  36.3  9.84§  NT¶  NT 
7  Anti-IgE  1 x  10-'  77.4  71.3  -1.26"*  <10  <10 
* In each case the histamine release curve was determined with seven different concentrations of 
ragweed antigen E or anti-IgE. The data presented is the stimulant concentration that gave the 
highest histamine release.  Antigen E  concentration in  ~g/ml; anti-IgE concentration in  ~g 
AbN/ml. 
$ Histamine release curves (virus vs. control) were compared by the paired t test by using data 
from the seven different concentrations of each stimulant, 
§P <  0.001  (df = 13). 
II UV-inactivated virus was used at an moi equivalence ofl in all cases except that of donor no. 6 
in which infectious virus was used, 
¶ Not tested. 
** P  >  0.1 (df = 13). 
individuals  to  UV-inactivated  HSV-1  resulted  in  enhanced  histamine  release. 
The  observation  that  inactivated  virus  was  capable  of enhancing  histamine 
release  in nonimmune  individuals  tended  to exclude  an immune-specific  mecha- 
nism  and  led us to  look at  the  possible  role  of virus-induced  interferon. 898  ENHANCEMENT  OF  IgE-MEDIATED  HISTAMINE  RELEASE 
Supernatant fluids from leukocyte cultures that had been incubated with 
virus (HSV-1) or control (PRK)  media (Table II) were assayed for interferon 
activity.  The  supernatant fluids of control cultures contained no  interferon 
activity. In contrast, in five out of six cases tested, the supernatant fluids from 
cultures exposed to virus contained interferon activity ranging from 20 to 320 U/ 
0.1 ml. The only exception was donor no. 7 whose leukocytes showed no increase 
in histamine release, and the interferon titer in the supernatant fluids was less 
than 10 U/0.1 ml. 
Time  Course of Enhanced Histamine Release: Relationship  to Interferon 
Activity in Supernatant Fluids.  To determine the minimum length of time 
between exposure of  leukocytes  to virus and development of  enhanced histamine 
release, leukocytes were exposed to UV-inactivated HSV-1  for 2 h. The viral 
inoculum was removed and the cells were washed and incubated at 37°C. At 4, 8, 
16, 24, and 48 h after initial exposure to virus, the leukocytes were challenged 
with anti-IgE. The data in Fig. 4 show significant enhancement of histamine 
release beginning at 8 h after exposure of cells to virus (P <  0.001). This effect 
increased progressively up to 48 h. 
To see if the enhancement  of histamine release was related to the presence of 
interferon, supernatant fluids collected at the different times were assayed for 
interferon activity. In all control cultures there was less than 10 U interferon/0.1 
ml.  In contrast, the interferon titer in the supernatant fluids from cultures 
treated with HSV-1 rose to 20 U by 8 h and was 320 U/0.1 ml by 24 h. 
Interferon  Induction  and  Enhanced  Histamine  Release  by  Different  Vi- 
ruses.  The data in Table III show that histamine release is enhanced by HSV- 
1, Influenza A, and Sendai virus, but not by SFV-7.  Between 20 and 160 U of 
interferorg0.1 ml were detected in the supernatant fluids from cultures treated 
with HSV-1, Influenza A, and Sendai virus, while less than 2 U of  interferon/0.1 
ml was found in supernatant fluids from cultures treated with SFV-7. 
Enhancement of Histamine Release by Supernatant Fluids from Leukocyte 
Cultures.  The previous experiments showed a  correlation between enhance- 
ment of histamine release and the presence of interferon in the supernatant 
fluids. To test whether interferon-containing supernatant fluids could transfer 
the capacity to enhance histamine release, supernatant fluids from cultures 24 h 
after exposure to UV-inactivated HSV-1 or PRK control media were added to 
fresh leukocytes. The interferon titer in the supernatant fluids from the HSV-1- 
treated cultures was 320 U/0.1 ml, while the interferon titer in the supernatant 
fluids from the PRK control cultures was less than 10 U/0.1 ml. These superna- 
tant fluids were incubated with fresh leukocytes for 24 h and the cells were then 
washed and challenged with ragweed antigen E and the amount of histamine 
released was determined. The data in Fig. 5 a demonstrate that the supernatant 
fluids from the HSV-l-treated cultures markedly enhanced the release of hista- 
mine (P <  0.001). 
To rule out the possibility that residual virus, rather than interferon, was 
responsible for the enhancement of histamine release, leukocyte cultures were 
stimulated with a nonviral interferon inducer. Cultures were exposed to poly 
I:poly C (20 ~g/ml) for 2 h, washed, reincubated for 22 h, and then exposed to 
ragweed antigen E. The data in Fig. 5 b show that treatment with poly I:poly C 50 
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Fro.  4.  Temporal relationship between the development of enhanced histamine release 
and interferon activity in the supernatant fluids.  Leukocytes  were  incubated with UV- 
inactivated HSV-1 for 2 h.  Cells were then washed and incubated in fresh medium. At 4, 8, 
16, 24, and 48 h after initial exposure to virus, supernatant fluids were collected and assayed 
for interferon activity. The cells were then challenged with anti-IgE and histamine release 
was determined, 
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TABLE  Ill 
Interferon Induction and Enhanced Histamine Release by Different Viruses 
Histamine release (%)$ 
Viruses*  t value 
Interferon titers 
(U/0.1 ml) 
Control  Virus  Control  Virus 
HSV-1  38.6  61.4  12.24§  <2  20 
Influenza A  33.6  56.7  10.91§  <2  160 
Sendai  33.6  54.5  9.76§  <2  160 
SFV-7  24.8  26.7  2.8311  <2  <2 
* Leukocytes were exposed to UV-inactivated viruses at an moi of 0.1 or an equivalent dilution of 
control media (PRK media or allantoic fluid). 
$ Leukocytes  were  challenged  with  nine  different  concentrations  of ragweed  antigen  E;  for 
statistical analysis the entire histamine release curves were compared by utilizing the paired t 
test. The data presented are the percent histamine release at the optimal ragweed antigen E 
concentration (3 × 10  -3 ~g/ml). 
§P  <  0.001 (df---  17). 
II P  >  0.1 (df = 17). 
resulted in an increase in histamine release (P < 0.001). The supernatant fluids 
from these cultures contained 40 U of interferon]0.1 ml, while the supernatant 
fluids from leukocyte cultures treated with control media contained no inter- 
feron. 
Enhancement of Histamine Release  by Interferon.  The effect of standard 
reference interferon on the enhancement of histamine release is illustrated in 
Fig. 5 c. Cells were incubated with either leukocyte  or flbroblast interferon  for 24 
h and then challenged with ragweed antigen E. Both preparations of interferon 
enhanced the release of histamine (P <  0.001). 
The effect of.different concentrations of leukocyte interferon on histamine 
release is  illustrated in Fig.  6.  The data show that as  the concentration of 
interferon was increased, the capacity of the cells to release histamine was 
correspondingly enhanced.  Statistically  significant enhancement was  found 
with 80 U or more of interferon  per milliliter (P < 0.001), but not with 8 U/ml (P 
>  0.01). 
To see if  the antiviral activity of  interferon  could be dissociated from the factor 
responsible  for enhancement of histamine release,  interferon samples were 
treated by: (a) dialysis (pH 2.0 for 24 h); (b) heat (65°C for 30 min); or (c) trypsin 
(0.002% trypsin for 1 h at 37°C). The treated samples were then tested for their 
ability to enhance histamine release and for their antiviral activity. The data in 
Table IV show that trypsin destroyed both the antiviral and the histamine- 
enhancing activity of the samples, while treatment with pH 2.0 or heat failed to 
destroy either activity. 
Since interferon is known to be species specific, the effect of mouse interferon 
on the release of histamine from human leukocytes was examined (Fig.  7). 
Statistical analysis of  the histamine release curves by paired t tests showed that 
mouse interferon produced significantly less enhancement  of histamine release 
(P >  0.01) than human interferon (P <  0.001). S.  IDA,  J.  J.  HOOKS,  R.  P.  SIRAGANIAN,  AND  A.  L.  NOTKINS 
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FIG.  5.  Enhancement of histamine release by interferon. Leukocytos were incubated with: 
(a) supernatant fluids from leukocyte cultures exposed to HSV-1 (320 interferon U/0.1 ml) 
or PRK control media (<10 interferon U/0.1 ml); (b) poly I:poly C  (20 pg/ml); (c) human 
leukocyte interferon (80 U/0.1 ml) or human fibroblast interferon (100 U/0.1 ml). After 24 h 
of incubation, leukocytes were challenged with ragweed antigen E  and histamine release 
was determined. 
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Discussion 
The present study showed that incubation of HSV-1, Influenza A, or Adeno-1 
viruses with human peripheral blood leukocytes failed to release histamine into 
the supernatant fluids.  If,  however, these  leukocyte  cultures were first incu- 
bated with virus and then challenged with ragweed antigen E  or anti-IgE, a 
marked enhancement of histamine release occurred. Both infectious and nonin- 902  ENHANCEMENT  OF  IgE-MEDIATED  HISTAMINE  RELEASE 
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Fro.  6,  Effect of interferon concentration on histamine release.  Leukocytes  were  incu- 
bated with 8, 80, or 800 U/ml of standard leukocyte interferon. After 24 h of incubation, cells 
were washed and challenged with anti-IgE, and histamine release was determined. 
TABLE  IV 
Relationship  between Antiviral and Histamine-Enhancing Activity of Preparations 
Containing Interferon 
Interferon 
Histamine 
titer  release (%)* 
(U/0.1 ml)  t 
Material  Treatment  value 
Con-  Con-  Inter-  Inter-  trol  trol 
feron  feron 
Media  Media 
Leukocyte  None  <5  80  12.6  26.2  8.82§ 
interferon  Dialysis (pH 7.2)  80  26.7  9.03§ 
Dialysis (pH 2.0)  80  31.5  9.37§ 
Heat (65°C,  30 min)  40  19.9  7.17§ 
Fibroblast  None  <5  100  14.4  35,0  8.87§ 
interferon  Trypsin  <5  <5  21.5  22.3  2.76il 
* Leukocytes were incubated with either control media (RPMI medium with 2% FBS) or interferon 
preparations  that  were  treated  in  different  ways.  After  24  h,  the  cells  were  washed  and 
challenged with seven different  concentrations of anti-IgE.  The histamine release  with the 
optimal anti-IgE concentration (3  x  10  -~ ~gAbN/ml) is presented. 
$ Histamine release curves (interferon vs. control) were statistically analyzed by the paired t test 
by using data from all seven concentrations of anti-IgE. 
§P <  0.001 (df = 13), 
[I P  >  0.01 (df = 13). 
fectious viruses were effective.  Examination of the culture fluids revealed that 
the enhancement of histamine release was associated with a soluble factor that 
had the properties of interferon.  Several  lines of evidence  indicate  that inter- 
feron, in fact, was responsible for the enhancement of histamine release.  First, 
all stimulants that enhanced histamine release  (i.e.,  viruses and poly I:poly C) 
also induced interferon. In contrast, stimulants that did not enhance histamine S.  IDA,  J.  J.  HOOKS,  R.  P.  SIRAGANIAN,  AND  A.  L.  NOTKINS  903 
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FIG.  7.  Species  specificity  of interferon.  Leukocytes  were  incubated with  800  U/ml  of 
human or mouse interferon. After 24 h of incubation, cells were washed and challenged with 
anti-IgE and histamine release was determined. 
release (Simian foamy virus, PRK cell control, allantoic fluids, RPMI medium) 
did not induce interferon (25). Second, there was a direct relationship between 
both the time of appearance and the amount of interferon in the culture fluids 
and the degree of histamine enhancement. Third, all preparations of human 
interferon, regardless of the tissue of origin (i.e. leukocytes or fibroblasts), were 
effective. Controls not containing interferon and heterologous interferon (i.e. 
mouse) were ineffective. Fourth, the soluble factor responsible for the enhance- 
ment of histamine release could not be dissociated from the antiviral activity of 
interferon by standard physicochemical means. Whether the enhancement of 
histamine release by interferon requires new RNA and protein synthesis (e.g., 
the reputed "antiviral protein" of  interferon) is presently under investigation. 
Since the basophils in human peripheral blood represent less than 1% of the 
total  leukocyte population,  the  majority  of the  virus-induced interferon in 
leukocyte cultures almost certainly comes from the other cell types (26). In an 
individual not immune to a particular virus, interferon could be nonspecifically 
induced by  the  interaction of that  virus  with  a  variety of cell  types  (e.g., 
lymphocytes, macrophages, fibroblasts). In an individual immune to a particu- 
lar virus, interferon could be specifically induced by the interaction of  that virus 
with immune lymphocytes (26). The resulting interferons, regardless of origin, 
could then act on the basophils to enhance histamine release. 
How interferon enhances histamine release is not clear. It is known that in 
preparations of  human leukocytes, histamine is present only in basophils. These 
basophils have specific receptors for IgE and such receptors are not present on 
other leukocytes (19, 27). The release of  histamine is triggered by the bridging of 
two IgE molecules on the basophil surface (28). The reaction can be initiated by 
either ragweed antigen E or anti-IgE and the two mechanisms appear identical 
(29). The release of histamine from the cell is a secretory process and does not 
result in cell death. This secretory process is modulated by the level of intracel- 
lular cyclic AMP, and agents such as isoproterenol, prostaglandin E, cholera 904  ENHANCEMENT  OF  IgE-MEDIATED  HISTAMINE  RELEASE 
toxin,  or  theophylline, which raise  intracellular levels of cyclic AMP,  will 
inhibit the release of histamine. Agents which either decrease cyclic AMP levels 
(e.g., imidazole, a-adrenergic compounds, PGF~), or increase cyclic GMP levels 
(e.g., exogenous cyclic GMP, carbamylcholine) have been reported to enhance 
histamine release from lung mast cells (30, 31), but thus far not from peripheral 
basophils (32). Microtubules and microfilaments  also play a role in this secretory 
process;  colchicine,  which  inhibits  microtubular  aggregation,  inhibits  the 
release reaction. Heavy water, which in many systems promotes microtubular 
aggregation, enhances histamine release and also reverses the action of colchi- 
cine (33, 34). Cytochalasin B, an agent known to disrupt microfilaments, also 
will enhance the IgE-mediated histamine release reaction (34-36). Whether or 
not interferon enhances histamine release by altering cyclic nucleotide levels, 
promoting microtubule aggregation, disrupting microfilaments, or some other 
mechanism remains to be determined. 
The demonstration here that interferon enhances histamine release repre- 
sents a hitherto unrecognized biological role for interferon. This points to the 
possibility that the induction of interferon may be one of the cofactors responsi- 
ble for precipitating or potentiating attacks of bronchial asthma during viral 
infections (2-17). Recent evidence from several laboratories indicates that inter- 
feron can suppress the growth of certain tumor cells and alter the functional 
response of cells of the immune system (for review, see reference 26). If it turns 
out that interferon acts on a common metabolic pathway (e.g., cyclic nucleotides 
or microtubule aggregation), interferon may modulate a variety of other biologi- 
cal processes. 
Summary 
Human leukocytes maintained in culture are induced to release histamine 
when exposed to ragweed antigen E or anti-IgE. Leukocyte cultures incubated 
with virus (i.e.  HSV-1,  Influenza A, and Adeno-1) but not exposed to ragweed 
antigen E or anti-IgE fail to release histamine. If, however, leukocyte cultures 
are first exposed to virus and then to ragweed antigen E or anti-IgE, significant 
enhancement  of histamine release occurs. Both infectious and inactivated virus 
enhance histamine release and the degree of enhancement is related to the 
concentration of virus and the length of the incubation. Tissue culture fluid 
harvested 8 h  after exposure of leukocytes to virus contains a  soluble factor 
which is capable of enhancing histamine release when added to fresh leukocyte 
cultures. This factor has all the properties of interferon including species speci- 
ficity and cannot be dissociated from the antiviral activity of interferon. More- 
over, both known inducers of interferon (poly I:poly C) and standard prepara- 
tions of interferon are capable of enhancing histamine release. The enhance- 
ment of histamine release by interferon represents a  new biological role for 
interferon. 
Received for publication 6 December 1976. 
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